These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 28582647)

  • 1. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.
    Morimoto A; Oh Y; Nakamura S; Shioda Y; Hayase T; Imamura T; Kudo K; Imashuku S;
    Cytokine; 2017 Sep; 97():73-79. PubMed ID: 28582647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of interleukin-1 receptor antagonist and tumor necrosis factor-alpha are elevated in children with Langerhans cell histiocytosis.
    Rosso DA; Ripoli MF; Roy A; Diez RA; Zelazko ME; Braier JL
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):480-3. PubMed ID: 12794527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum osteopontin levels in pediatric patients with high risk Langerhans cell histiocytosis.
    Oh Y; Morimoto A; Shioda Y; Imamura T; Kudo K; Imashuku S;
    Cytokine; 2014 Dec; 70(2):194-7. PubMed ID: 25086462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF-V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first-line therapy.
    Wang CJ; Zhu T; Zhao CZ; Cui H; Wang D; Zhao ZJ; Huang XT; Li HL; Liu FF; Zhang R; Li ZG; Cui L
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31099. PubMed ID: 38845144
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.
    Murakami I; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Nagata K; Horie Y; Hayashi K; Imamura T; Morimoto A; Imashuku S; Gogusev J; Jaubert F; Takata K; Oka T; Yoshino T
    Cell Commun Signal; 2015 Feb; 13():13. PubMed ID: 25889448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of soluble interleukin 2 receptor (sIL-2R), tumor necrosis factor-alpha (TNF-α), and immunoglobulin M are correlated with the disease extent in childhood Langerhans cell histiocytosis.
    Wang W; Liu X; Yang S; Peng X; Ma Y; Xiong X; Li Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11431-11442. PubMed ID: 37389594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment.
    Egeler RM; Favara BE; van Meurs M; Laman JD; Claassen E
    Blood; 1999 Dec; 94(12):4195-201. PubMed ID: 10590064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A circulating subset of BRAF
    Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
    Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
    Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
    J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].
    Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
    McClain KL; Picarsic J; Chakraborty R; Zinn D; Lin H; Abhyankar H; Scull B; Shih A; Lim KPH; Eckstein O; Lubega J; Peters TL; Olea W; Burke T; Ahmed N; Hicks MJ; Tran B; Jones J; Dauser R; Jeng M; Baiocchi R; Schiff D; Goldman S; Heym KM; Wilson H; Carcamo B; Kumar A; Rodriguez-Galindo C; Whipple NS; Campbell P; Murdoch G; Kofler J; Heales S; Malone M; Woltjer R; Quinn JF; Orchard P; Kruer MC; Jaffe R; Manz MG; Lira SA; Parsons DW; Merad M; Man TK; Allen CE
    Cancer; 2018 Jun; 124(12):2607-2620. PubMed ID: 29624648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Prevalence of
    Liu X; Zhang Y; Zhou CX
    Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of plasma interleukin-17A are associated with severe neurological sequelae in Langerhans cell histiocytosis.
    Ismail MB; Åkefeldt SO; Lourda M; Gavhed D; Aricò M; Henter JI; Delprat C; Valentin H
    Cytokine; 2020 Feb; 126():154877. PubMed ID: 31629106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.